Somatropin Market Summary

Key Factors Driving Somatropin Growth

1. Large and persistent treatment need in growth hormone deficiency (GHD): Somatropin remains an established recombinant human growth hormone for children and adults with GHD, with additional pediatric indications including Turner syndrome, chronic kidney disease, Prader-Willi syndrome, small for gestational age (SGA), and idiopathic short stature. The continued diagnosis and treatment of these conditions provides a durable patient base for somatropin products. Importantly, adult GHD remains substantially undertreated: a 2025 US real-world analysis cited by Ascendis identified 54,310 patients at risk of adult GHD, but only 3.1% were receiving growth-hormone treatment, indicating significant room for treatment penetration to increase.

2. Expansion of the growth-hormone market through long-acting formulations: Although traditional somatropin requires daily subcutaneous injections, the broader hGH market is increasingly shifting toward less-frequent administration. Weekly growth-hormone products such as somapacitan and somatrogon are helping expand the overall treated population by addressing injection burden and adherence. Novo Nordisk reported that Sogroya sales reached DKK 2 billion in 2025, compared with DKK 1 billion in 2024, while Norditropin generated approximately DKK 4 billion in 2025; combined Norditropin/Sogroya hGH sales were approximately DKK 6 billion in 2025.

3. Strong clinical and commercial acceptance of established somatropin brands: Leading daily somatropin products—including Norditropin, Genotropin, Omnitrope and Zomacton—continue to have broad regulatory and commercial presence. The US market, for example, still includes multiple daily somatropin products, while major pharmaceutical companies maintain established manufacturing, physician relationships and reimbursement infrastructure. This mature commercial ecosystem supports continued use of somatropin despite competition from newer long-acting GH therapies.

4. Growth of once-weekly alternatives is expanding the overall GH treatment opportunity: Newer long-acting products are not simply replacing daily somatropin; they can make GH therapy more convenient and potentially improve persistence. Novo Nordisk reported that Sogroya gained significant momentum in 2025 following international consensus guidance that standardized pediatric GHD diagnosis, dosing and weekly monitoring. The company also expanded Sogroya into France, Argentina and Canada, with further market entries planned for 2026.

5. Expansion into additional growth-disorder indications: The addressable population is increasing as long-acting GH therapies receive broader indications. In February 2026, the FDA approved Sogroya for children aged 2.5 years and older with idiopathic short stature, SGA without catch-up growth, or Noonan syndrome, in addition to GHD. Novo Nordisk stated that Sogroya consequently had the broadest range of approved indications among long-acting growth hormones. Such label expansion demonstrates the opportunity for the somatropin/GH therapeutic class to reach patient populations beyond conventional GHD.

Somatropin Recent Developments

In July 2026, VISEN Pharmaceuticals announced the commercial launch of its core product lonapegsomatropin in Mainland China. Lonapegsomatropin is a prodrug of somatropin administered once weekly, providing sustained release of active, unmodified somatropin, indicated in China for the treatment of children with growth hormone deficiency (GHD). Its first prescription issued at Shanghai, marking a milestone in patient access in the region. As an innovative biopharmaceutical company focusing on endocrinology, VISEN Pharmaceuticals has thus taken a significant step from R&D to commercialization. The Phase III clinical trial in China demonstrated non-inferiority and superiority over daily somatropin in annualized height velocity (AHV) among treatment-naive Chinese PGHD patients.

“Somatropin Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Somatropin for approved indication like Somatotropin deficiency and Turner’s syndrome; as well as potential indication like Prader-Willi syndrome and Short stature in the 7MM. A detailed picture of Somatropin’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Somatropin for approved and potential indications. The Somatropin market report provides insights about Somatropin’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Somatropin performance, future market assessments inclusive of the Somatropin market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Somatropin sales forecasts, along with factors driving its market.

Somatropin Drug Summary

Somatropin is a recombinant human growth hormone (rhGH) that is structurally identical to endogenous human growth hormone and is used primarily to promote growth and regulate metabolism. It acts by binding to growth hormone receptors on target tissues, stimulating the production of insulin-like growth factor-1 (IGF-1), which promotes longitudinal bone growth, protein synthesis, and tissue development while also influencing carbohydrate and lipid metabolism. Somatropin is administered primarily through subcutaneous injection, with dosing adjusted according to the patient’s age, body weight, indication, and clinical response. It is approved for several growth-related disorders, including growth hormone deficiency in children and adults, growth failure associated with conditions such as Turner syndrome, chronic kidney disease, Prader-Willi syndrome, and children born small for gestational age who fail to demonstrate adequate catch-up growth, depending on the specific product and regulatory jurisdiction. In adults, it may be used for confirmed growth hormone deficiency to help improve body composition, bone health, exercise capacity, and quality of life. Somatropin is available under multiple brand names and formulations from different manufacturers and remains an established therapy in pediatric endocrinology and growth hormone replacement. The report provides Somatropin’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Somatropin Market Report

The report provides insights into:

• A comprehensive product overview including the Somatropin MoA, description, dosage and administration, research and development activities in approved indications like Somatotropin deficiency and Turner’s syndrome; as well as potential indication like Prader-Willi syndrome and Short stature.
• Elaborated details on Somatropin regulatory milestones and other development activities have been provided in Somatropin market report.
• The report also highlights Somatropin‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Somatropin market report also covers the patents information, generic entry and impact on cost cut.
• The Somatropin market report contains current and forecasted Somatropin sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Somatropin market report also features the SWOT analysis with analyst views for Somatropin in approved and potential indications.

Methodology

The Somatropin market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Somatropin Analytical Perspective by DelveInsight

• In-depth Somatropin Market Assessment

This Somatropin sales market forecast report provides a detailed market assessment of Somatropin for approved indication like Somatotropin deficiency and Turner’s syndrome; as well as potential indication like Prader-Willi syndrome and Short stature in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Somatropin sales data uptil 2034.

• Somatropin Clinical Assessment

The Somatropin market report provides the clinical trials information of Somatropin for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Somatropin Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Somatropin Market Potential & Revenue Forecast

• Projected market size for the Somatropin and its key indications
• Estimated Somatropin sales potential (Somatropin peak sales forecasts)
• Somatropin Pricing strategies and reimbursement landscape

Somatropin Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Somatropin Market positioning compared to existing treatments
• Somatropin Strengths & weaknesses relative to competitors

Somatropin Regulatory & Commercial Milestones

• Somatropin Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Somatropin Clinical Differentiation

• Somatropin Efficacy & safety advantages over existing drugs
• Somatropin Unique selling points

Somatropin Market Report Highlights

• In the coming years, the Somatropin market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Somatropin companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Somatropin’s dominance.
• Other emerging products for Somatotropin deficiency and Turner’s syndrome; as well as potential indication like Prader-Willi syndrome and Short stature are expected to give tough market competition to Somatropin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Somatropin in approved and potential indications.
• Analyse Somatropin cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Somatropin sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Somatropin in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Somatropin? How strong is Somatropin’s clinical and commercial performance?
• What is Somatropin’s clinical trial status in each individual indications such as Somatotropin deficiency and Turner’s syndrome; as well as potential indication like Prader-Willi syndrome and Short stature and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Somatropin Manufacturers?
• What are the key designations that have been granted to Somatropin for approved and potential indications? How are they going to impact Somatropin’s penetration in various geographies?
• What is the current and forecasted Somatropin market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Somatropin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Somatropin for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Somatropin? What is the duration of therapy and what are the geographical variations in cost per patient?